Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis

A. J. McCullough, W. N. Stassen, R. H. Wiesner, A. J. Czaja

Research output: Contribution to journalArticle

Abstract

To evaluate the diagnostic significance of the amino-terminal propeptide of procollagen type III (P-III-P) in monitoring chronic liver disease, serum P-III-P concentrations were measured in 46 patients with severe chronic active hepatitis (CAH) at entry and at remission during a therapeutic clinical trial. Coded sera were analyzed for P-III-P concentrations by both a standard radioimmunoassay and a recently developed and potentially more precise radioimmunoassay that uses Fab fragments rather than intact antibodies for binding antigen. As compared with conditions in 22 normal controls, P-III-P concentrations were elevated in 98% and 72% of patients with CAH by use of the standard and Fab radioimmunoassays, respectively. With treatment, P-III-P levels fell at remission to levels that were not significantly different from control values, as measured by both assays. The Fab radioimmunoassay, either alone or combined with the standard radioimmunoassay, provided no advantage over the standard radioimmunoassay alone. Serum P-III-P levels, as measured by either assay, correlated poorly or not at all with standard liver function tests and with histologic grade of disease. These data suggest that P-III-P serum levels are abnormal in severe CAH but normalize when remission of disease has been achieved. Consequently, serum P-III-P levels may be a diagnostic aid in the sequential evaluation of patients with severe CAH requiring treatment, and this test deserves further investigation. In this regard, the standard P-III-P assay has greater diagnostic accuracy than the Fab assay. Because the serum P-III-P measurement correlated with neither the histologic assessment of CAH nor the standard indices of inflammatory activity, it is not a quantitative measure of inflammation, but rather may reflect the associated dynamic process of collagen synthesis.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalJournal of Laboratory and Clinical Medicine
Volume109
Issue number1
StatePublished - 1987
Externally publishedYes

Fingerprint

Collagen Type III
Chronic Hepatitis
Peptides
Radioimmunoassay
Assays
Serum
Liver
procollagen Type III-N-terminal peptide
Immunoglobulin Fab Fragments
Liver Function Tests
Liver Diseases
Chronic Disease
Collagen
Therapeutics
Clinical Trials
Inflammation
Antigens

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis. / McCullough, A. J.; Stassen, W. N.; Wiesner, R. H.; Czaja, A. J.

In: Journal of Laboratory and Clinical Medicine, Vol. 109, No. 1, 1987, p. 55-61.

Research output: Contribution to journalArticle

McCullough, A. J. ; Stassen, W. N. ; Wiesner, R. H. ; Czaja, A. J. / Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis. In: Journal of Laboratory and Clinical Medicine. 1987 ; Vol. 109, No. 1. pp. 55-61.
@article{0d4c2fa6dde54ae4b24ce6dd310a6bfc,
title = "Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis",
abstract = "To evaluate the diagnostic significance of the amino-terminal propeptide of procollagen type III (P-III-P) in monitoring chronic liver disease, serum P-III-P concentrations were measured in 46 patients with severe chronic active hepatitis (CAH) at entry and at remission during a therapeutic clinical trial. Coded sera were analyzed for P-III-P concentrations by both a standard radioimmunoassay and a recently developed and potentially more precise radioimmunoassay that uses Fab fragments rather than intact antibodies for binding antigen. As compared with conditions in 22 normal controls, P-III-P concentrations were elevated in 98{\%} and 72{\%} of patients with CAH by use of the standard and Fab radioimmunoassays, respectively. With treatment, P-III-P levels fell at remission to levels that were not significantly different from control values, as measured by both assays. The Fab radioimmunoassay, either alone or combined with the standard radioimmunoassay, provided no advantage over the standard radioimmunoassay alone. Serum P-III-P levels, as measured by either assay, correlated poorly or not at all with standard liver function tests and with histologic grade of disease. These data suggest that P-III-P serum levels are abnormal in severe CAH but normalize when remission of disease has been achieved. Consequently, serum P-III-P levels may be a diagnostic aid in the sequential evaluation of patients with severe CAH requiring treatment, and this test deserves further investigation. In this regard, the standard P-III-P assay has greater diagnostic accuracy than the Fab assay. Because the serum P-III-P measurement correlated with neither the histologic assessment of CAH nor the standard indices of inflammatory activity, it is not a quantitative measure of inflammation, but rather may reflect the associated dynamic process of collagen synthesis.",
author = "McCullough, {A. J.} and Stassen, {W. N.} and Wiesner, {R. H.} and Czaja, {A. J.}",
year = "1987",
language = "English (US)",
volume = "109",
pages = "55--61",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis

AU - McCullough, A. J.

AU - Stassen, W. N.

AU - Wiesner, R. H.

AU - Czaja, A. J.

PY - 1987

Y1 - 1987

N2 - To evaluate the diagnostic significance of the amino-terminal propeptide of procollagen type III (P-III-P) in monitoring chronic liver disease, serum P-III-P concentrations were measured in 46 patients with severe chronic active hepatitis (CAH) at entry and at remission during a therapeutic clinical trial. Coded sera were analyzed for P-III-P concentrations by both a standard radioimmunoassay and a recently developed and potentially more precise radioimmunoassay that uses Fab fragments rather than intact antibodies for binding antigen. As compared with conditions in 22 normal controls, P-III-P concentrations were elevated in 98% and 72% of patients with CAH by use of the standard and Fab radioimmunoassays, respectively. With treatment, P-III-P levels fell at remission to levels that were not significantly different from control values, as measured by both assays. The Fab radioimmunoassay, either alone or combined with the standard radioimmunoassay, provided no advantage over the standard radioimmunoassay alone. Serum P-III-P levels, as measured by either assay, correlated poorly or not at all with standard liver function tests and with histologic grade of disease. These data suggest that P-III-P serum levels are abnormal in severe CAH but normalize when remission of disease has been achieved. Consequently, serum P-III-P levels may be a diagnostic aid in the sequential evaluation of patients with severe CAH requiring treatment, and this test deserves further investigation. In this regard, the standard P-III-P assay has greater diagnostic accuracy than the Fab assay. Because the serum P-III-P measurement correlated with neither the histologic assessment of CAH nor the standard indices of inflammatory activity, it is not a quantitative measure of inflammation, but rather may reflect the associated dynamic process of collagen synthesis.

AB - To evaluate the diagnostic significance of the amino-terminal propeptide of procollagen type III (P-III-P) in monitoring chronic liver disease, serum P-III-P concentrations were measured in 46 patients with severe chronic active hepatitis (CAH) at entry and at remission during a therapeutic clinical trial. Coded sera were analyzed for P-III-P concentrations by both a standard radioimmunoassay and a recently developed and potentially more precise radioimmunoassay that uses Fab fragments rather than intact antibodies for binding antigen. As compared with conditions in 22 normal controls, P-III-P concentrations were elevated in 98% and 72% of patients with CAH by use of the standard and Fab radioimmunoassays, respectively. With treatment, P-III-P levels fell at remission to levels that were not significantly different from control values, as measured by both assays. The Fab radioimmunoassay, either alone or combined with the standard radioimmunoassay, provided no advantage over the standard radioimmunoassay alone. Serum P-III-P levels, as measured by either assay, correlated poorly or not at all with standard liver function tests and with histologic grade of disease. These data suggest that P-III-P serum levels are abnormal in severe CAH but normalize when remission of disease has been achieved. Consequently, serum P-III-P levels may be a diagnostic aid in the sequential evaluation of patients with severe CAH requiring treatment, and this test deserves further investigation. In this regard, the standard P-III-P assay has greater diagnostic accuracy than the Fab assay. Because the serum P-III-P measurement correlated with neither the histologic assessment of CAH nor the standard indices of inflammatory activity, it is not a quantitative measure of inflammation, but rather may reflect the associated dynamic process of collagen synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0023070845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023070845&partnerID=8YFLogxK

M3 - Article

C2 - 3794515

VL - 109

SP - 55

EP - 61

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 1

ER -